- Report
- March 2025
- 184 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Clinical Trials
- June 2024
- 60 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Report
- May 2024
- 129 Pages
Global
From €6178EUR$6,499USD£5,190GBP
From €4040EUR$4,250USD£3,394GBP
- Report
- May 2022
- 151 Pages
Global
From €4230EUR$4,450USD£3,554GBP
- Report
- August 2022
- 99 Pages
North America
From €3280EUR$3,450USD£2,755GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4706EUR$4,950USD£3,953GBP
- Report
- June 2023
- 159 Pages
Global
From €7130EUR$7,500USD£5,990GBP
- Report
- June 2023
- 80 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- August 2024
- 96 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- May 2022
- 166 Pages
Global
From €1901EUR$2,000USD£1,597GBP

Chemotherapy Induced Peripheral Neuropathy (CIPN) is a type of peripheral neuropathy caused by certain chemotherapy drugs. It is a common side effect of chemotherapy, and can cause pain, numbness, tingling, and burning sensations in the hands and feet. CIPN drugs are used to treat the symptoms of CIPN, and can include anticonvulsants, antidepressants, and opioids. These drugs are used to reduce pain, improve nerve function, and improve quality of life.
CIPN drugs are part of the larger Central Nervous System (CNS) drug market, which includes drugs used to treat neurological disorders such as Alzheimer's disease, Parkinson's disease, and epilepsy. The CNS drug market is a rapidly growing market, driven by the increasing prevalence of neurological disorders and the development of new treatments.
Some companies in the CIPN drug market include Pfizer, Novartis, Merck, and Johnson & Johnson. These companies are involved in the development and marketing of CIPN drugs, as well as other CNS drugs. Show Less Read more